Celltrion sets fresh earnings record on newer biosimilars

Celltrion has turned in yet another record quarterly earnings report on growing sales of its newer biosimilar portfolio and improving manufacturing efficiency.

According to the Korean biopharmaceutical company on Monday, it logged 1.4 trillion won ($950 million) in sales and 451.8 billion won in operating profit in the April to June period, up 45 percent and 86.3 percent, respectively, from the same period in 2025.

The company previously posted record-setting sales of 1.145 trillion won and an o ...